Adverse Effect of Nano-Silicon Dioxide on Lung Function of Rats with or without Ovalbumin Immunization by Han, Bing et al.
Adverse Effect of Nano-Silicon Dioxide on Lung Function
of Rats with or without Ovalbumin Immunization
Bing Han
1., Jing Guo
1., Tesfamariam Abrahaley
1, Longjuan Qin
1, Li Wang
1, Yuduo Zheng
1, Bing Li
1,
Dandan Liu
1, Hanchao Yao
1, Jiwen Yang
1, Changming Li
3, Zhuge Xi
2*, Xu Yang
1*
1Laboratory of Environmental Sciences and Hubei Key Laboratory of Genetic Regulation and Integrative Biology, Huazhong Normal University, Wuhan, China, 2Tianjin
Institutes of Health and Environmental Medicine, Tianjin, China, 3Division of Bioengineering, Nanyang Technology University, Singapore, Singapore
Abstract
Background: The great advances of nanomaterials have brought out broad important applications, but their possible
nanotoxicity and risks have not been fully understood. It is confirmed that exposure of environmental particulate matter
(PM), especially ultrafine PM, are responsible for many lung function impairment and exacerbation of pre-existing lung
diseases. However, the adverse effect of nanoparticles on allergic asthma is seldom investigated and the mechanism
remains undefined. For the first time, this work investigates the relationship between allergic asthma and nanosized silicon
dioxide (nano-SiO2).
Methodology/Principal Findings: Ovalbumin (OVA)-treated and saline-treated control rats were daily intratracheally
administered 0.1 ml of 0, 40 and 80 mg/ml nano-SiO2 solutions, respectively for 30 days. Increased nano-SiO2 exposure
results in adverse changes on inspiratory and expiratory resistance (Ri and Re), but shows insignificant effect on rat lung
dynamic compliance (Cldyn). Lung histological observation reveals obvious airway remodeling in 80 mg/ml nano-SiO2-
introduced saline and OVA groups, but the latter is worse. Additionally, increased nano-SiO2 exposure also leads to more
severe inflammation. With increasing nano-SiO2 exposure, IL-4 in lung homogenate increases and IFN-c shows a reverse but
insignificant change. Moreover, at a same nano-SiO2 exposure concentration, OVA-treated rats exhibit higher (significant) IL-
4 and lower (not significant) IFN-c compared with the saline-treated rats. The percentages of eosinophil display an
unexpected result, in which higher exposure results lower eosinophil percentages.
Conclusions/Significance: This was a preliminary study which for the first time involved the effect of nano-SiO2 to OVA
induced rat asthma model. The results suggested that intratracheal administration of nano-SiO2 could lead to the airway
hyperresponsiveness (AHR) and the airway remolding with or without OVA immunization. This occurrence may be due to
the Th1/Th2 cytokine imbalance accelerated by the nano-SiO2 through increasing the tissue IL-4 production.
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Introduction
Environmental particulate matter (PM), especially the ultrafine
PM, has been reported to be harmful to human health and
exposure to PM from air pollution can lead to lung function
impairment and exacerbation of pre-existing lung diseases,
including chronic obstructive pulmonary disease (COPD) or
asthma [1–3]. Diesel exhaust particles (DEPs) are the main
component of PM and are characterized as a carbonic nucleus to
absorb approximately 18,000 different high-molecular-weight
organic compounds, of which the toxicities are known to be
responsible for several diseases and inflammations of lung as well
as many extrapulmonary syndromes [4–6]. Ambient PM is
believed to promote lung inflammation through oxidative stress
and lipid peroxidation [7]. Previous studies have demonstrated
that DEPs can also exaggerate lipopolysaccharide-induced lung
inflammation, representing an innate immunity-dominant lung
inflammation [8], as well as OVA-induced lung inflammation, an
adaptive immunity-dominant lung inflammation [9,10].
In addition to conventional particles, recent innovations in
nanotechnology have increased the availability of a new type of
material described as nanoparticles [11,12]. Nanoparticles are
engineered structures with diameter #100 nm. They have been
widely used in many fields, including medicine, microelectronics,
photography, and pharmaceutical and cosmetic industries [11–
13], but their possible hazards and risks have not been fully
investigated to keep pace with their advances. Inhalation is the
primary pathway through which we are exposed to nano-particles,
the absorption of skin and ingestion of gut tract also contribute to
the exposure of it [11]. Although in vitro and in vivo studies have
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monary toxicity [14–16], the mechanisms of these effects have not
been extensively studied yet.
Asthma is a chronic lung disease with symptoms of obstruction
of inhalation and exhalation caused by excess mucus production
and swelling in airway membranes, leading to coughing and
wheezing. Asthma cannot be completely healed or cured and thus
needs continuous medical treatment, resulting in a large burden
on society [17]. Allergic asthma is characterized by unbalance of
Th1/Th2 cell and recruitment of type 2 T helper (Th2) cells.
These cells release cytokines (e.g. IL-4, IL-5, and IL-13) to
promote inflammatory cell influx, airway remodeling and AHR,
while the production of type 1 T helper (Th1) cell’s cytokines (e.g.
IFN-c and IL-2) is suppressed accordingly [18–20].
As a major component of the earth’s crust, SiO2 has been
known for its toxicity since ancient times [21,22]. By virtue of its
unique properties such as high specific surface area and adjustable
pore size, nano-SiO2 has been recently employed in biosciences
and medicines. Various silica nanoparticles have been used as
drug vehicles or target-specific contrast agents for imaging [23].
Most previous studies have focused on conventional nano-SiO2
toxicities, such as silicosis, pulmonary tuberculosis, interstitial
fibrosis, and emphysema, but the linkage between allergic asthma
and silica dust exposure has not been studied [24]. Thus, the
present study is designed in particular to evaluate the effect of
nano-SiO2 on allergic asthma by exposing an OVA-treated rat to
nano-SiO2-exposure solutions within intratracheally administered
for 30 days.
Materials and Methods
Silica nanomaterials
Silica nanoparticles with diameters of 10–20 nm, 99.5% purity
and BET surface area ranged from 140–180 m
2/g were purchased
from Sigma-Aldrich (USA). Scanning electron microscopy (SEM)
images of the material were obtained by JEOL-6700F (Fig. 1) and
compared with an SEM image of normal-sized SiO2 (nor-SiO2,5 –
10 mm, Sinopharm, China) taken previously. The distilled water
was used to prepare the mother solution (800 mg/ml). The
prepared mother solution was sterilized at 120uC for 20 min to
avoid the aggregation of nano-SiO2 induce by various microbes
during our experimental period. The mother solution was daily
stirred for 1 h followed by ultrasonicating for another hour to
avoid clumping before each use. The exposure solutions (40 and
80 mg/ml) were freshly prepared by diluting the mother solution in
distilled water and were ultrasonificated for another 15 min before
its intretracheal instillation. After this process, both exposure
solutions were stable for at least 24 h. Because the exposure
solutions were freshly prepared before use, so sterilization for the
two exposure solutions were not conducted.
Animals and study protocol
Male Wistar rats (6–7 weeks old) were purchased from the
Hubei experimental animal center (Wuhan, China), fed a
commercial diet, and gave water ad libitum. The rats were
housed in pathogen-free cages at 20–25uC and 50–70% relative
humidity. The protocol of this study is shown in Figure 2. Rats
were randomly divided into 6 experimental groups with 9 rats per
group. The OVA-treated groups (group D, E and F) had OVA
sensitization through subcutaneous injection of 1 ml of 200 mg/
mL OVA solution containing 6.5 mg gelatinous Al(OH)3 (Sigma,
USA) as an adjuvant at day 4, 18, and 25, followed by an aerosol
challenge with 1% OVA for 30 min using an ultrasonic nebulizer
(Yuyue, version 402AI, China) from days 31 to 37. Similar
procedure was performed on the saline-treated groups (group A, B
and C) in which OVA was replaced by saline. The exposure
period lasted 30 d (from day 1 to 30), in which rats were instilled
daily intratracheally with 0.1 ml of 1 of the 2 exposure solutions
discussed above or saline. Finally, the rats were sacrificed at day 38
for further biochemical and histological analysis. This protocol was
Figure 1. SEM images of nano-SiO2 (a) and nor-SiO2 (b). (JEOL-6700F).
doi:10.1371/journal.pone.0017236.g001
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Huazhong Normal University with Certification on Application
for the Use of Animals dated May 20
th, 2007. All procedures
strictly adhered to the guidelines from the National Committee of
Animal Care and Use in the experiments.
Intratracheal administration
Instillation of tested particles is usually employed in studies of
particle toxicology [25]. To precisely control lung exposure to the
tested material, the solutions were instilled intratracheally to the
rats. Such a practice greatly reduced the rat suffering and
concurrently achieved the experimental needs. In more detail, a
rat had been forced to inhale ether vapor until it lost acupuncture
response. The dosage and inhalation time of ether for each rat
varied because different rat possess different physiological charac-
teristic. Its body was then suspended ventral side outward on an
incline by hooking its incisors on a small metal loop at the top of the
incline and a light located above the rat’s chest. The tongue of the
rat was then gently pulled out with tweezers, allowing the airway to
be clearly observed by light-penetrating its chest, and 0.1 ml of
exposure solution or saline was instilled into the lung through a
syringe-mounted stainless steel tube inserted into the airway.
Lung function measurement
Airway hyper-responsiveness (AHR) assessment was conducted for
24 h after the final aerosol challenge by using the AniRes2005 lung
function system (Bestlab, version 2.0, China) according to the
manufacturer’s instructions. After anesthetization by intraperitoneal
injection of 1% pentobarbital sodium (Urchem, China), the
respiration of the rat was maintained by a computer-controlled small
animal ventilator connected to the rat through a tracheal cannula.
The respiratory rate and the time ratio of expiration/inspiration were
preset at 75/min and 1.5:1, respectively. An injector needle was then
inserted into the rat jugular vein, through which 0.025, 0.05, 0.1 and
0.2 mg/kg body weight methacholine (O-Acetyl-b-methylcholine
chloride, MCH, Sigma, USA) were injected successively at a 5 min-
intervals. After each injection, Ri, Re R-areas (the graphic area
between the peak value and baseline) and the valley value of Cldyn
[26] were recorded for further analysis.
Bronchoalveolar lavage (BAL) and cell counting
Following measurement of AHR, the lung of each rat was
lavaged in situ with 3 successive 1 ml volumes of saline instilled by
syringe. After gentle pressing of the rat chest several times, BAL
fluids were collected and combined. All recovery ratios of different
rats were around 90%. Then, 1 ml of BAL fluid was centrifuged at
1000 rpm for 10 min at 4uC. The sediment was then resuspended
in 1 ml of saline and the total cell content of 200 ml aliquots was
counted by hemocytometer. Another 400 ml of the cell suspension
was centrifuged again and resuspended in 400 ml of a mixed
solution containing 20 ml 2% Eosin Y sodium solution (Amresco,
high purity grade, USA), 20 ml of acetone and 360 ml of deionized
water. After this process, only the eosinophils were available in the
solution. The eosinophils were then counted by hemocytometer.
The results expressed as percent of eosinophils in the total cell
count ((eosinophils/total cells) 6100%).
IL-4 and IFN-c measurements
After BAL processing, the right lung was removed, and glass-
made homogenizers were used for preparation of a 10% tissue
Figure 2. Study protocol. (A) Saline treatment plus 0 mg/ml nano-SiO2 exposure. (B) Saline treatment plus 40 mg/ml nano-SiO2 exposure. (C) Saline
treatment plus 80 mg/ml nano-SiO2 exposure. (D) OVA treatment plus 0 mg/ml nano-SiO2 exposure. (E) OVA treatment plus 40 mg/ml nano-SiO2
exposure. (F) OVA treatment plus 80 mg/ml nano-SiO2 exposure. All rats were sacrificed on day 38.
doi:10.1371/journal.pone.0017236.g002
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according to the manufacturers’ instructions, by using commercial
ELISA kits (IL-4 kit, Bender MedSystems, Germany; IFN-c kit,
Dakewe, China).
Lung histological assay
After BAL processing, the left lung was harvested for
histological assay. Tissue pretreatments and preparation of
hematoxylin and eosin (H&E) stained slices were carried out as
previously described [27] and all slices were examined under a
microscope (Leica DM 4000B, Germany).
Statistical analysis
Covariance analysis was performed with the AHR assessment data
using the Statistical Product and Service Solutions (SPSS, version
13.0)to calculate Fand p values. p,0.05 was considered as significant
difference and p,0.01 was considered as extremely significant
difference. Data from the other measurements were analyzed by
using Origin software (version 8.0). p,0.05 was considered as
significant difference and p,0.01 was considered as extremely
significant difference. All data were reported as means 6SE.
Results
SEM image Comparison between nano-SiO2 and nor-SiO2
The SEM of nano-SiO2 particles in Fig. 1, b displays aggregated
as clumps of nanoparticles, while that of nor-SiO2 particles in
Fig. 1, a illustrates large slab-shaped forms.
Airway hyper-responsiveness assessment
Three parameters of the lung function (Ri, Re and Cydln) were
recorded after each injection of MCH (0.025, 0.05, 0.1 and
0.2 mg/kg) (Fig. 3). Generally, Ri and Re values were higher in
OVA groups (group D, E and F) in comparison to the saline
groups (group A, B and C) (Ri, F=64.898, p,0.01; Re,
F=83.118, p,0.01), and the higher exposure concentration of
nano-SiO2 resulted in an upward shift in the Ri and Re curves (Ri,
F=6.460, p,0.01; Re, F=19.059, p,0.01). A downward shift of
the Cydln curves were detected as nano-SiO2 increased, but the
different nano-SiO2 exposure concentrations appeared to have no
significant effect (F=0.597, p.0.05) on Cldyn. Moreover, the
saline groups demonstrated higher Cydln values than the OVA
groups (F=21.874, p,0.01).
Figure 3. AHR assessment. I & II: Ri of saline groups and OVA groups, FnanoSiO2=6.460 (p=0.002) and FOVA=64.898 (p=0.000). III & IV: Re of saline
groups and OVA groups, FnanoSiO2=19.059 (p=0.000) and FOVA=83.118 (p=0.000). V & VI: Cldyn of saline groups and OVA groups, FnanoSiO2=0.597
(p=0.552) and FOVA=21.874 (p=0.000).
doi:10.1371/journal.pone.0017236.g003
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The eosinophil percentages appeared to indicate an unexpected
tendency of that a dose-dependent decline existed in the OVA
groups when the exposure concentration increased (Fig. 4). 40 mg/
ml nano-SiO2-introduced OVA group (group E) demonstrated
significant decrease of eosinophil percentage (p,0.05) when
compared with the OVA-alone group without the introduced
nanoparticles (group D), and 80 mg/ml nano-SiO2-introduced
OVA group (group F) was extremely lower (p,0.01) compared
with that of the OVA-alone group (group D). The eosinophil
percentages of the saline groups also showed decreased tendency,
but not significant. Furthermore, the eosinophil percentage in the
80 mg/ml nano-SiO2-introduced OVA group (group F) was
extremely lower than that of 80 mg/ml nano-SiO2-introduced
saline group (group C).
IL-4 and IFN-c measurement
In saline groups or OVA groups, IL-4 content rose as the
exposure concentration increased (Fig. 5). Moreover, the IL-4
content of the OVA groups was much higher than that in the
saline groups (0 mg/ml: p,0.01, 40 mg/ml: p,0.05, 80 mg/ml:
p,0.01) at a same nano-SiO2 exposure concentration. There was
an extremely increase (p,0.01) in the 80 mg/ml nano-SiO2-
introduced saline group (group C) when compared with the saline-
alone group (group A). Significant increase (p,0.05) was also
observed in the 80 mg/ml nano-SiO2-introduced OVA group
(group F) in comparison to the OVA-alone group (group D).
A slight dose-dependent character of IFN-c contents was
observed in the 10% pulmonary homogenates (Fig. 6). In the
saline groups or OVA groups, higher nano-SiO2 concentration led
to lower, but not significant IFN-c content. Generally, the saline
groups (groups A, B and C) had higher IFN-c contents than that in
the OVA groups (groups D, E and F), but insignificantly.
Lung histological assay
Representative images of the lung tissue slices in Figure 7
exhibits slices, possibly evidencing aggravated inflammation
occurred in nano-SiO2-introduced saline groups (group B and
C) and all OVA groups (group D, E and F). Obvious changes in
the airway structures were observed in the 80 mg/ml nano-SiO2-
Figure 4. Eosinophil percentages in BAL fluids ((Eosinophils/
total cells) 6100%). (A) Saline treatment plus 0 mg/ml nano-SiO2
exposure. (B) Saline treatment plus 40 mg/ml nano-SiO2 exposure. (C)
Saline treatment plus 80 mg/ml nano-SiO2 exposure. (D) OVA treatment
plus 0 mg/ml nano-SiO2 exposure. (E) OVA treatment plus 40 mg/ml
nano-SiO2 exposure. (F) OVA treatment plus 80 mg/ml nano-SiO2
exposure. # p,0.05, ## p,0.01, all compared with (D). ++ p,0.01,
comparisons between the same exposure concentration groups.
doi:10.1371/journal.pone.0017236.g004
Figure 5. IL-4 concentrations. (A) Saline treatment plus 0 mg/ml
nano-SiO2 exposure. (B) Saline treatment plus 40 mg/ml nano-SiO2
exposure. (C) Saline treatment plus 80 mg/ml nano-SiO2 exposure. (D)
OVA treatment plus 0 mg/ml nano-SiO2 exposure. (E) OVA treatment
plus 40 mg/ml nano-SiO2 exposure. (F) OVA treatment plus 80 mg/ml
nano-SiO2 exposure. ** p,0.01, compared with (A). # p,0.05,
compared with (D). + p,0.05, ++ p,0.01, comparisons between the
same exposure concentration groups.
doi:10.1371/journal.pone.0017236.g005
Figure 6. IFN-c concentrations. (A) Saline treatment plus 0 mg/ml
nano-SiO2 exposure. (B) Saline treatment plus 40 mg/ml nano-SiO2
exposure. (C) Saline treatment plus 80 mg/ml nano-SiO2 exposure. (D)
OVA treatment plus 0 mg/ml nano-SiO2 exposure. (E) OVA treatment
plus 40 mg/ml nano-SiO2 exposure. (F) OVA treatment plus 80 mg/ml
nano-SiO2 exposure. No significant difference among groups.
doi:10.1371/journal.pone.0017236.g006
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remodeling appeared in the 80 mg/ml nano-SiO2-introduced
OVA group (group F).
Discussion
Unlike nor-SiO2, which possesses relatively larger sizes and
sharper forms to cause possible physical cell damages (Fig. 1), the
adverse effect of nano-SiO2 is most likely due to the nanoparticle
biological toxicity. The diameter of silica nanoparticles used in this
study ranged from 10–20 nm (Fig. 1) allows their easy access to the
respiratory system and further introduce chemical or/and
biological toxicity [11]. Respirable crystalline silica has been
reported to be responsible for many diseases. Therefore, exposure
limits during its use have been set by many organizations
[24,28,29]. According to these limits and our research goal, the
rats in this work were treated daily with intratracheal instillation of
0.1 ml of 0, 40, 80 mg/ml nano-SiO2 exposure solution,
respectively. To simulate the real environmental exposure, 30
daily low dose instillations were administrated rather than few
immediately high dose exposures before any allergen challenge.
The classic theory propounds that type I hypersensitivity is
involved in the pathogenesis of allergic asthma, in which the AHR,
airway remodeling and airway inflammation are 3 major
characters of it [30,18]. Bronchial hyperreactivity to pharmaco-
logical agents [18], one of the most important clinical discoveries
in occupational asthma studies, was observed in our AHR
assessment results (Fig. 3). The MCH challenge is a useful tool
in diagnosis of allergic respiratory disorders and has been widely
used in assessing airway responsiveness [31]. MCH as a
pharmacological agent can cause increased Ri/Re and decreased
Cydln. The inhalation, tail vein injection and jugular vein
injection are three main administrations of MCH, but we found
out that airborne MCH could coagulate before it enter the airway
to jeopardize the accuracy of MCH challenge dose. Although the
tail vein injection is an easy approach to conduct MCH challenge,
Figure 7. Representative histological images of H&E stained rats’ lung. (A) Saline treatment plus 0 mg/ml nano-SiO2 exposure. (B) Saline
treatment plus 40 mg/ml nano-SiO2 exposure. (C) Saline treatment plus 80 mg/ml nano-SiO2 exposure. (D) OVA treatment plus 0 mg/ml nano-SiO2
exposure. (E) OVA treatment plus 40 mg/ml nano-SiO2 exposure. (F) OVA treatment plus 80 mg/ml nano-SiO2 exposure. Slices microscopically
examined at original magnification of 206(Leica DM 4000B, Germany).
doi:10.1371/journal.pone.0017236.g007
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long travel from tail to lung. Consequently, after the pilot study,
we chose the jugular vein injection for the MCH challenge, which
could meet all the requests.
The R-areas of the respiratory resistances (Ri and Re) observed
here explain the variation in the large airways, while the change of
Cldyn represents the state of small airways or the parenchyma
[26,27]. The Ri and Re graphs (Fig. 3) show that increased nano-
SiO2 exposure results in an upward shift of the curves (Ri/Re,
p,0.01), suggesting that nano-SiO2 has an adverse effect on the
large airways of the lung. A similar but reversed effect appears in
the Cydln results, in which higher exposure causes a slight
downward shift of the curves (p=0.552), so the effects of nano-
SiO2 on small airways or the parenchyma are not significant.
According to these results, we propose that this is mainly because
nano-SiO2 particles have been deposited in the large airways
before reaching the small airways. Other studies have reported
that ultrafine particles (,100 nm) can settle effectively in the
alveolar region [12]. However, we believe that this should be
attributed to the intratracheal instillation used in the present
protocol, in which the nano-SiO2 particles (10–20 nm) are
suspended in the liquid instead of air when entering into the
airways.
The pulmonary histological assay (Fig. 7) evidences various
degrees of inflammation appeared in all 6 cases. Considering the
ether employed in the intratracheal instillation, we believe that the
inflammations are partially caused by toxicity of ether. Addition-
ally, diseases induced by SiO2 such as silicosis, industrial
bronchitis, emphysema may also contribute to these inflamma-
tions. However, the higher nano-SiO2 exposure groups (both
OVA groups and saline groups) appear to have more severe
inflammation (inflammatory cell influx) than the lower groups, and
generally more serious inflammation is found in the OVA groups
compared with saline groups. Wall thickening, subepithelial
fibrosis, mucous metaplasia, deposition of extracellular matrix in
the subepithelial layer, myofibroblast hyperplasia, bronchial
smooth muscle hyperplasia and hypertrophy, hyperplasia of
submucosal glands, and increase of submucosal vessels have been
defined as structural alterations to represent the remodeling
manifestations of asthma [32,33]. Based on these characteristics,
obvious airway remodeling has been found in both 80 mg/ml
nano-SiO2-introduced saline (group C) and OVA group (group F),
but the latter has more severe degree of remodeling. Additionally,
in the AHR assessment, Ri and Re volumes are generally higher in
the OVA groups compared with the saline groups (Ri, F=64.898,
p,0.01; Re, F=83.118, p,0.01; Fig. 4), and rats treated with
saline shows increased Cydln volumes compared with OVA-
treated rats (Cldyn, F=21.874, p,0.01). Thus, both AHR
assessment and pulmonary histological assay suggests that nano-
SiO2 nanoparticle-treatment has stronger adverse effect on OVA
rats than that on saline rats.
One of the fundamental features of allergic asthma has been
thought to be the eosinophilic airway inflammation [18].
Therefore, eosinophilic percentage is chosen here as a major
biomarker for allergic asthma, but our result indicates an
unexpected dose-dependent pattern, in which the biomarker
decreases rather than increases with increased nano-SiO2
exposure, especially in the OVA groups (Fig. 4). Unfortunately,
the method used here is restricted to only the eosinophilic
percentage. However, some studies have proposed that the typical
eosinophilic pattern occurs in a minority of subjects and a
noneosinophilic pattern is a distinct phenotype of asthma [34,35].
Indeed, particulate air pollution has been thought to be a trigger
for noneosinophilic airway inflammation in asthma [36]. Here, in
light of the unexpected opposite pattern showed from the results,
we speculate that nano-SiO2 may has been involved into the
development and exacerbation of noneosinophilic asthma. How-
ever, further studies are needed to confirm this hypothesis with
assessment of various inflammatory cells, cytokines and chemo-
tactic molecules in BAL fluid.
Animal models for asthma have been used for over 100 years
and considered as an ideal vehicle for testing and identifying the
mechanisms behind the asthmatic phenotype. With appropriate
methods, rat asthma models not only demonstrate increased
responsiveness to nonspecific bronchoconstricting agents but also
acute responses to allergen inhalation [37]. There are a plethora of
approaches for building rat asthma models with different goals
[38–42]. We have applied the protocol described above to create
our own rat asthma model, in which more severe effects of AHR
(Fig. 3) and airway remodeling (Fig. 7) can exist in the OVA-alone
group (group D) compared with the saline-alone group (group A).
Moreover, the OVA-alone group (group D) also possesses higher
IL-4 content (Fig. 5) and lower IFN-c content (Fig. 6) compared
with the saline-alone group (group A). The eosinophilis percent-
ages of group A and group D are not statistically different, and
they all generally higher than those of other similar asthma models
[39,41]. However, before the administration of bronchoalveolar
lavage, the lung function measurement, as a little surgery, might
have created a mask effect and affected the eosinophilic
percentages of the two groups (group A and D), respectively.
Moreover, 30 daily consecutive intratracheal instillations we
applied can also have the side effects even the exposure material
is saline, which should also be considered. Nevertheless, the
difference of inflammations between group A and group D can be
clearly seen in H&E stained slices (Fig. 7A, D).
In animal asthmatic models, the Th1/Th2 cell balance is
disturbed and Th2 cells are dominant in the airway. These cells
induce IgE production and airway inflammation by producing
Th2 cytokines such as IL-4, IL-5, and IL-13. The disturbance of
the Th1/Th2 balance is also accompanied by decrease of Th1
cytokines such as IFN-c and IL-2 [18–20]. Our experimental
results show that the higher nano-SiO2 concentration induces rise
of IL-4 content in the saline groups (group A, B and C) and the
OVA groups (group D, E and F) (Fig. 5). Although the IFN-c
content barely declines after nano-SiO2 exposure in all groups
(Fig. 6), we are convinced that nano-SiO2 could lead to a tissue IL-
4 increase with or without OVA, which may, in turn, accelerate
the Th1/Th2 cytokine imbalance and aggravate the symptoms of
OVA-induced asthma such as AHR (Fig. 3) and airway
remodeling (Fig. 7).
Immunological regulation is a very complex system where many
things are still unknown. Nano-SiO2 may interact with one or
some certain triggers located in the upstream of IL-4 generative
pathway, and then promote the release of IL-4. According to the
result of tissue IL-4 (Fig. 5), we can easily find that the IL-4
contents in the 80 mg/ml exposure groups (group C and F) are
significantly higher than the control groups (group A and D),
respectively. However, insignificant difference between 40 mg/ml
exposure groups (group B and E) and control groups (group A and
D) are also obvious, respectively. Therefore, we propose that there
should be a threshold level of nano-SiO2 between 40 mg/ml and
80 mg/ml for IL-4 generating.
The relationship between SiO2 and the immune-mediated
respiratory diseases, especially the allergic asthma, are seldom
studied. This study demonstrates for the first time that intratra-
cheal instillation of SiO2 nanoparticles could develop and
exacerbate AHR and airway remolding with or without OVA
immunization. This manifestation may attribute to the Th1/Th2
Effect of Nano-SiO2 on Rat Lung Function
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the tissue IL-4 production. Additionally, nano-SiO2 nanoparticles
may also involve in the development and exacerbation of
noneosinophilic inflammation, which is definitely worthy of
further study.
Acknowledgments
The authors are grateful to Dr Zhisong Lu (School of Chemical and
Biomedical Engineering, Nanyang Technological University). The author
Xu Yang also would like to thank the Center of Advanced Bionanosystems,
Nanyang Technological University for technology support.
Author Contributions
Conceived and designed the experiments: XY BH ZX. Performed the
experiments: BH JG LQ LW DL YZ BL JY. Analyzed the data: BH XY.
Contributed reagents/materials/analysis tools: XY HY. Wrote the paper:
BH XY CL TA.
References
1. Li N, Xia T, Nel AE (2008) The role of oxidative stress in ambient particulate
matter-induced lung diseases and its implications in the toxicity of engineered
nanoparticles. Free Radic Biol Med 44(9): 1689–1699.
2. Ling SH, van Eeden SF (2009) Particulate matter air pollution exposure: role in
the development and exacerbation of chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis 4: 233–243.
3. Liu L, Poon R, Chen L, Frescura AM, Montuschi P, et al. (2009) Acute effects of
air pollution on pulmonary function, airway inflammation, and oxidative stress
in asthmatic children. Environ Health Perspect 117(4): 668–674.
4. Delfino RJ (2002) Epidemiologic evidence for asthma and exposure to air toxics:
linkages between occupational, indoor, and community air pollution research.
Environ Health Perspect 110(Suppl 4): 573–589.
5. Mazzarella G, Ferraraccio F, Prati MV, Annunziata S, Bianco A, et al. (2007)
Effects of diesel exhaust particles on human lung epithelial cells: an in vitro
study. Respir Med 101(6): 1155–1162.
6. Kampa M, Castanas E (2008) Human health effects of air pollution. Environ
Pollut 151(2): 362–367.
7. Pereira CE, Heck TG, Saldiva PH, Rhoden CR (2007) Ambient particulate air
pollution from vehicles promotes lipid peroxidation and inflammatory responses
in rat lung. Braz J Med Biol Res 40(10): 1353–1359.
8. Yanagisawa R, Takano H, Inoue K, Ichinose T, Sadakane K, et al. (2003)
Enhancement of acute lung injury related to bacterial endotoxin by components
of diesel exhaust particles. Thorax 58(7): 605–612.
9. Takano H, Yoshikawa T, Ichinose T, Miyabara Y, Imaoka K (1997) Diesel
exhaust particles enhance antigen-induced airway inflammation and local
cytokine expression in mice. Am J Respir Crit Care Med 156(1): 36–42.
10. Samuelsen M, Nygaard UC, Løvik M (2008) Allergy adjuvant effect of particles
from wood smoke and road traffic. Toxicology 246(2–3): 124–131.
11. Hoyt VW, Mason E (2008) Nanotechnology: Emerging health issues. Chem
Health Saf 15(2): 10–15.
12. Yang W, Peters JI, Williams RO, 3rd (2008) Inhaled nanoparticles–a current
review. Int J Pharm 356(1–2): 239–247.
13. Savolainen K, Alenius H, Norppa H, Pylkka ¨nen L, Tuomi T, et al. (2010) Risk
assessment of engineered nanomaterials and nanotechnologies–a review.
Toxicology 269(2–3): 92–104.
14. Kobayashi N, Naya M, Endoh S, Maru J, Yamamoto K, et al. (2009)
Comparative pulmonary toxicity study of nano-TiO(2) particles of different sizes
and agglomerations in rats: different short- and long-term post-instillation
results. Toxicology 264(1–2): 110–118.
15. Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, et al. (2009)
Histological analysis of 70-nm silica particles-induced chronic toxicity in mice.
Eur J Pharm Biopharm 72(3): 626–629.
16. Su Y, Xu JY, Shen P, Li J, Wang L, et al. (2010) Cellular uptake and cytotoxic
evaluation of fullerenol in different cell lines. Toxicology 269(2-3): 155–159.
17. (2000) Asthma. Nat Biotechnol 18( Suppl): IT10–1.
18. Karol MH (1994) Animal models of occupational asthma. Eur Respir J 7(3):
555–568.
19. Herz U, Renz H, Wiedermann U (2004) Animal models of type I allergy using
recombinant allergens. Methods 32(3): 271–280.
20. Park HJ, Lee CM, Jung ID, Lee JS, Jeong YI, et al. (2009) Quercetin regulates
Th1/Th2 balance in a murine model of asthma. Int Immunopharmacol 9(3):
261–267.
21. Ding M, Chen F, Shi X, Yucesoy B, Mossman B, et al. (2002) Diseases caused by
silica: mechanisms of injury and disease development. Int Immunopharmacol
2(2–3): 173–182.
22. Park R, Rice F, Stayner L, Smith R, Gilbert S, et al. (2002) Exposure to
crystalline silica, silicosis, and lung disease other than cancer in diatomaceous
earth industry workers: a quantitative risk assessment. Occup Environ Med
59(1): 36–43.
23. Suh WH, Suslick KS, Stucky GD, Suh YH (2009) Nanotechnology,
nanotoxicology, and neuroscience. Prog Neurobiol 87(3): 133–170.
24. NIOSH (2002) NIOSH HAZARD REVIEW–Health Effects of Occupational
Exposure to Respirable Crystalline Silica. National Institute for Occupational
Safety and Health. Publication No. 2002–2129.
25. SCENIHR (2007) The appropriateness of the risk assessment methodology in
accordance with the technical guidance documents for new and existing
substances for assessing the risks of nanomaterials. Scientific Committee on
Emerging and Newly-Identified Health Risks.
26. Drazen JM, Finn PW, De Sanctis GT (1999) Mouse models of airway
responsiveness: physiological basis of observed outcomes and analysis of selected
examples using these outcome indicators. Annu Rev Physiol 61: 593–625.
27. Qiao Y, Li B, Yang G, Yao H, Yang J, et al. (2009) Irritant and adjuvant effects
of gaseous formaldehyde on the ovalbumin-induced hyperresponsiveness and
inflammation in a rat model. Inhal Toxicol 21(14): 1200–1207.
28. OSHA (2009) Controlling Silica Exposures in Construction. Occupational
Safety and Health Administration, U.S. Department of Labor. OSHA 3362-04
2009.
29. AIOH (2009) AIOH Position Paper on Respirable Crystalline Silica and
Occupational Health Issues. Australian Institute of Occupational Hygienists Inc.
30. Wills-Karp M (1999) Immunologic basis of antigen-induced airway hyperre-
sponsiveness. Annu Rev Immunol 17: 255–281.
31. Brusasco V, Crimi E (2001) Methacholine provocation test for diagnosis of
allergic respiratory diseases. Allergy 56(12): 1114–1120.
32. Elias JA (2000) Airway remodeling in asthma. Unanswered questions.
Am J Respir Crit Care Med 161(3 Pt 2): S168–171.
33. Yamauchi K (2006) Airway remodeling in asthma and its influence on clinical
pathophysiology. Tohoku J Exp Med 209(2): 75–87.
34. Gibson PG, Simpson JL, Saltos N (2001) Heterogeneity of airway inflammation
in persistent asthma: evidence of neutrophilic inflammation and increased
sputum interleukin-8. Chest 119(5): 1329–1336.
35. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG (2008) Clarithromycin
targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit
Care Med 177(2): 148–155.
36. Douwes J, Gibson P, Pekkanen J, Pearce N (2002) Non-eosinophilic asthma:
importance and possible mechanisms. Thorax 57(7): 643–648.
37. Zosky GR, Sly PD (2007) Animal models of asthma. Clin Exp Allergy 37(7):
973–988.
38. Carvalho C, Jancar S, Mariano M, Sirois P (1999) A rat model presenting
eosinophilia in the airways, lung eosinophil activation, and pulmonary
hyperreactivity. Exp Lung Res 25(4): 303–316.
39. Hylkema MN, Hoekstra MO, Luinge M, Timens W (2002) The strength of the
OVA-induced airway inflammation in rats is strain dependent. Clin Exp
Immunol 129(3): 390–396.
40. Liu S, Chihara K, Maeyama K (2005) The contribution of mast cells to the late-
phase of allergic asthma in rats. Inflamm Res 54(5): 221–228.
41. de Oliveira AP, Domingos HV, Cavriani G, Damazo AS, Dos Santos
Franco AL, et al. (2007) Cellular recruitment and cytokine generation in a rat
model of allergic lung inflammation are differentially modulated by progesterone
and estradiol. Am J Physiol Cell Physiol 293(3): C1120–1128.
42. Kucharewicz I, Kasacka I, Pawlak D, Tankiewicz-Kwedlo A, Mroczko B, et al.
(2008) The concentration of kynurenine in rat model of asthma. Folia Histochem
Cytobiol 46(2): 199–203.
Effect of Nano-SiO2 on Rat Lung Function
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17236